Vivian Fonseca, MD
Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Dr. Fonseca serves on the clinical practice committee of the American Diabetes Association (current chairman) and the joint ADA/ACC “Make the Link” Program. He is the President of Medicine & Science for the American Diabetes Association
He is editor-in-chief of Diabetes Care since 2007, having formerly been associate editor. He was until 2006 editor-in-chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006). He is an ad hoc reviewer for several other journals including New England Journal of Medicine,JAMA, Diabetes, Diabetic Medicine, Kidney International, the American Journal of Clinical Nutrition, the British Medical Journal, and Metabolism.
Dr. Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians ( London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on several national and international committees, and has published over 200 papers, review articles and book chapters.
Dr. Fonseca's current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. He has a research program evaluating homocysteine and inflammation as risk factors for heart disease in diabetes. He is currently the principal investigator of the DRMS (diabetes remote management system) study, a study aimed at evaluating the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with Type 2 Diabetes Mellitus. Dr. Fonseca is also the principal investigator of the Zemplar study, a study investigating the effects of Zemplar (paricalcitol) on endothelial function and inflammation in patients with Type 2 Diabetes Mellitus and stage 3 or 4 chronic kidney disease.
He is also the principal investigator of the ACCORDION study, an NIH sponsored, multicenter follow –up study to the ACCORD study which examined cardiovascular risk and diabetes. Dr. Fonseca is also the principal investigator for the BEACON study, a multicenter study evaluating the effects of bardoxolone methyl in patients with chronic kidney disease and Type 2 diabetes. Dr. Fonseca has lectured in the United States and abroad, and his publications include more than 180 articles. He is the editor of the text book "Clinical Diabetes: Translating Research into Practice" (El Sevier 2006) and several monographs and book chapters.
Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V.The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.J Diabetes Complications. 2012 Jun 12. [Epub ahead of print]PMID: 22699113
Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators.Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.Lancet. 2012 Jun 16;379(9833):2262-9. Epub 2012 Jun 9.PMID:22683131
Fonseca VA, Kirkman MS, Darsow T, Ratner RE.The american diabetes association diabetes research perspective.Diabetes. 2012 Jun;61(6):1338-45. No abstract available. PMID: 22618769
Fonseca V.Journal of diabetes and its complications.J Diabetes Complications. 2012 Mar;26(2):69. Epub 2012 Apr 10. No abstract available. PMID: 22494838
Zhao Y, Campbell CR, Fonseca V, Shi L.Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes.Diabetes Care. 2012 May;35(5):1126-32. Epub 2012 Mar 19.PMID: 22432106
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; on behalf of the EFC6018 GetGoal-Mono Study Investigators.Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).Diabetes Care. 2012 Jun;35(6):1225-1231. Epub 2012 Mar 19.PMID: 22432104
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R.Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).Diabetes Care. 2012 Mar;35(3):485-7. Epub 2012 Feb 1.PMID: 22301126
Fonseca V, Zhu T, Karyekar C, Hirshberg B.Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.Diabetes Obes Metab. 2012 Apr;14(4):365-71. doi: 10.1111/j.1463-1326.2011.01553.x. Epub 2012 Jan 18.
Handelsman Y, Fonseca V, Rosenstock J.Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan;5(1):43-54.
Fonseca V, Zhu T, Karyekar C, Hirshberg B.Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.Diabetes Obes Metab. 2012 Apr;14(4):365-71
Liu S, Zhao Y, Hempe JM, Fonseca V, Shi L.Economic burden of hypoglycemia in patients with Type 2 diabetes.Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):47-51.
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R.Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).Diabetes Care. 2012 Mar;35(3):485-7. Epub 2012 Feb 1.
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; on behalf of the EFC6018 GetGoal-Mono Study Investigators.Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).Diabetes Care. 2012 Mar 19. [Epub ahead of print]
Zhao Y, Campbell CR, Fonseca V, Shi L.Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes.Diabetes Care. 2012 Mar 19. [Epub ahead of print]
Zhao Y, Liu J, Zhao Y, Thethi T, Fonseca V, Shi L. Predictors of Duloxetine versus Other Treatments among Veterans with Diabetic Peripheral Neuropathic Pain: A Retrospective Study. Pain Pract. 2011 Sep 27. [Epub ahead of print]
Katsiki N, Papanas N, Mikhailidis DP, Fonseca VA. Glycated hemoglobin A(1c) (HbA(1c)) and diabetes: a new era? Curr Med Res Opin. 2011 Sep 14. [Epub ahead of print]
Fonseca VA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol. 2011 Aug 2;108(3 Suppl):52B-8B. Review.
Krause MW, Fonseca VA, Shah SV. Combination inhibition of the renin-angiotensin system: is more better? Kidney Int. 2011 Aug;80(3):245-55. Epub 2011 Jun 1.
Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab. 2011 Sep;13(9):814-22.
Tina K. Thethi, MD, MPH1, Aster Sigel1, Japa Shanker, PhD1, Roberta McDuffie, MSN, ACNS-BC, BSBA, CDE1, Shamsa Ali, MD1, Ajaz Banka, MD1, Nick Avitabile, MD1, Amna Khan, MD1, C. Lillian Yau, PhD2, Vivian Fonseca, MD1. Polymorphisms of the endocannabinoid system in obese African American women. Journal of Investigative Medicine, 2011, Feb, Vol 59, No 2, (492), page 510
Wildman RP, McGinn AP, Kim M, Muntner P, Wang D, Cohen HW, Ogorodnikova AD, Reynolds K, Fonseca V. Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk. Diabetes Care. 2011 Mar;34(3):746-8. Epub 2011 Feb 1. PMID:21285391 [PubMed - in process]
Avitabile N, Banka A, Fonseca VA. Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. Expert Opin Drug Saf. 2011 Mar;10(2):305-10. Epub 2011 Jan 19. PMID:21244342 [PubMed - in process]
Fonseca VA. Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca. Am J Med. 2011 Jan;124(1 Suppl):S54-61. Review. PMID:21194580 [PubMed - indexed for MEDLINE]
Toprani A, Fonseca V. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. PMID: 21205120 [PubMed - in process]
Thethi TK, Parsha K, Rajapurkar M, Mukhopadhyay B, Shah S, Yau CL, Japa S, Fonseca V. Urinary catalytic iron in obesity. Clin Chem. 2011 Feb;57(2):272-8. Epub 2010 Dec 28. PMID:21189275 [PubMed - indexed for MEDLINE
Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC Jr, Probstfield J, Yau CL, Shah S, Christians U, Buse J, Fonseca V. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. Clin Chem. 2011 Feb;57(2):341-4. Epub 2010 Dec 15. No abstract available. PMID:21159897 [PubMed - indexed for MEDLINE]
Sacks DB, Fonseca V, Goldfine AB. Diabetes: advances and controversies. Clin Chem. 2011 Feb;57(2):147-9. Epub 2010 Dec 13. No abstract available. PMID:21149500 [PubMed - indexed for MEDLINE]
Goldfine AB, Fonseca V, Shoelson SE. Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem. 2011 Feb;57(2):162-7. Epub 2010 Nov 22. Review. PMID:21098138 [PubMed - indexed for MEDLINE}
Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Impaired Vascular Reactivity In African-American Patients With Type 2 Diabetes Mellitus And Microalbuminuria or Proteinuria Despite Angiotensin Converting Enzyme Inhibitor Therapy. J Clin Endocrinol Metab. 2006; 91:31-35.
Fonseca VA. Insulin resistance, diabetes, hypertension, and Renin-Angiotensin system inhibition: reducing risk for cardiovascular disease. J Clin Hypertens ( Greenwich ) 2006; 8(10):713-720
Fonseca V. Newly diagnosed diabetes/hyperglycemia in hospitals: what should we do? Endocr Pract 2006; 12 Suppl 3:108-111.
Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients. Vascul Pharmacol 2006; 45(1):29-35
Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29(4):759-764.
Fonseca VA , Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications 2006; 20(1):14-20.
Vasudevan AR, Burns A, Fonseca VA. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 2006; 5(5):273-286.
Fonseca VA. Insulin resistance, diabetes, hypertension, and Renin-Angiotensin system inhibition: reducing risk for cardiovascular disease. J Clin Hypertens ( Greenwich ) 2006; 8(10):713-720.
Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpin D, Fonseca V. Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin. Metabol Synd Rel Disorders Sep 2006, 4: 179-184
Fonseca VA , Kahn SE. Of HOPEs and DREAMs: the quest to prevent type 2 diabetes. J Clin Endocrinol Metab 2006; 91(12):4762-4763.
Jawa A, Fonseca V. Cardiovascular effects of insulin sensitizers in diabetes. Curr Opin Investig Drugs 2006; 7(9):806-814.
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Fonseca V et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115(1):114-126.
Fonseca V . Diabetes care: building on strength. Diabetes Care 2007; 30(1):1-2.
Shah SV, Baliga R, Rajapurkar M, Fonseca VA .Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18(1):16-28.
Fonseca V. Management of diabetes in the hospital. Rev Cardiovasc Med. 2006;7 Suppl 2:S1
Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007; 30:734-43.
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Mar 27; [Epub ahead of print]
McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS. Beta-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007; 9:408-17.
Swaminathan S, Fonseca VA, Alam MG, Shah SV. The Role of Iron in Diabetes and its Complications. Diabetes Care. 2007 Apr 11; [Epub ahead of print]
1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 email@example.com